ProMIS Neurosciences is trading 5.6% down at $14.13, despite the broader market moving higher on August 12, 2026; no clear company-specific announcement explains the decline.
- The company is scheduled to report second-quarter 2026 financial results and provide a business update on August 13.
- Investors may be positioning ahead of the event, but available evidence does not establish it as the direct cause.
- Recent positive Alzheimer’s trial data was reported July 28, not August 12.